A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer

Gynecologic Oncology

Volumn 123, Issue 3, 2011, Pages 486-491

  Adams, Sarah F ^a   Marsh, Evelyn B ^a   Elmasri, Wafic ^b   Halberstadt, Steffanie ^a   Vandecker, Stephanie ^c   Sammel, Mary D ^a   Bradbury, Angela R ^c   Daly, Mary ^c   Karlan, Beth ^b   Rubin, Stephen C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

BRCA mutations; Doxil therapy; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DOXORUBICIN; PLATINUM;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 81155139687     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.032     Document Type: Article

References (26)

1. S.C. Rubin BRCA-related ovarian carcinoma Cancer 97 9 May 1 2003 2127 2129
2. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2 Jan 21 2009 80 87
3. H.A. Risch, J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley, and E. Kwan Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 3 Mar 2001 700 710 (Pubitemid 32203724)
4. S.M. Domchek, and T.R. Rebbeck Prophylactic oophorectomy in women at increased cancer risk Curr Opin Obstet Gynecol 19 1 Feb 2007 27 30 (Pubitemid 46095869)
5. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 May 1 2003 2187 2195 (Pubitemid 36444059)
6. C. Gourley, C.O. Michie, P. Roxburgh, T.A. Yap, S. Harden, and J. Paul Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype J Clin Oncol 28 15 May 20 2010 2505 2511
7. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, and S. Shanley "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 34 Dec 1 2008 5530 5536
8. W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, J. Higgins, and C. Friedman Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 7182 Feb 28 2008 1116 1120 (Pubitemid 351317449)
9. E.M. Swisher, W. Sakai, B.Y. Karlan, K. Wurz, N. Urban, and T. Taniguchi Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 8 Apr 15 2008 2581 2586 (Pubitemid 351556255)
10. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 7035 Apr 14 2005 913 917 (Pubitemid 40559005)
11. G. Aubel-Sadron, and D. Londos-Gagliardi Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review Biochimie 66 5 May 1984 333 352 (Pubitemid 14058895)
12. A.N. Gordon, C.O. Granai, P.G. Rose, J. Hainsworth, A. Lopez, and C. Weissman Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer J Clin Oncol 18 17 Sep 2000 3093 3100
13. M. Markman, A. Kennedy, K. Webster, G. Peterson, B. Kulp, and J. Belinson Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel- refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum Gynecol Oncol 78 3 Pt 1 Sep 2000 369 372
14. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 10 Suppl May 15 2003 187s 193s
15. G. Gossner, R.L. Coleman, D.G. Mutch, N.S. Horowitz, J.S. Rader, and R.K. Gibb CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan Gynecol Oncol 103 1 Oct 2006 212 218 (Pubitemid 44374691)
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 Feb 2 2000 205 216
17. A.N. Gordon, M. Tonda, S. Sun, and W. Rackoff Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 1 Oct 2004 1 8 (Pubitemid 39286270)
18. J.T. Thigpen, C.A. Aghajanian, D.S. Alberts, S.M. Campos, A.N. Gordon, and M. Markman Role of pegylated liposomal doxorubicin in ovarian cancer Gynecol Oncol 96 1 Jan 2005 10 18 (Pubitemid 39612410)
19. G. Gorumlu, Y. Kucukzeybek, M. Kemal-Gul, B. Karaca, M. Cosan-Terek, and B. Karabulut Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients J BUON 13 3 Jul-Sep 2008 349 352
20. I. Alagkiozidis, A. Facciabene, C. Carpenito, F. Benencia, Z. Jonak, and S. Adams Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 J Transl Med 7 2009 104
21. N. Casares, M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, and N. Chaput Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 12 Dec 19 2005 1691 1701 (Pubitemid 41815875)
22. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, and J.L. Perfettini Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 1 Jan 2007 54 61 (Pubitemid 46067386)
23. A. Cabanes, S. Even-Chen, J. Zimberoff, Y. Barenholz, E. Kedar, and A. Gabizon Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2 Clin Cancer Res 5 3 Mar 1999 687 693 (Pubitemid 29131981)
24. B. Clarke, A.V. Tinker, C.H. Lee, S. Subramanian, M. van de Rijn, and D. Turbin Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 3 Mar 2009 393 402
25. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P.A. Vasey Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 20 Jul 10 2010 3323 3329
26. M.O. Nicoletto, C. Falci, D. Pianalto, G. Artioli, P. Azzoni, and G. De Masi Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer Gynecol Oncol 100 2 Feb 2006 318 323 (Pubitemid 43075263)